Khanduri S, Dodwell D J
Cookridge Hospital, Yorkshire Centre of Clinical Oncology, Hospital Lane, Leeds LS16 6QB, UK.
Breast. 2008 Feb;17(1):76-9. doi: 10.1016/j.breast.2007.07.034. Epub 2007 Sep 5.
Recent evidence shows aromatase inhibitors (AIs) to be of benefit over tamoxifen in the adjuvant setting. It is also apparent that musculoskeletal symptoms associated with AIs may be a significant problem in the clinical setting. The aim of this article is to review the data on AIs with respect to musculoskeletal symptoms in the adjuvant setting.
A review on the literature relating to AIs in the adjuvant setting and musculoskeletal symptoms.
Results of phase III trials show lower incidence of musculoskeletal symptoms than reported in the clinical setting.
AIs offer a significant advantage over tamoxifen. More research is required to ascertain the cause and to define the spectrum of musculoskeletal symptoms reported in women taking AIs. Decision of appropriate treatment should be made jointly between clinician and patient after full discussion of the risks and benefits.
近期证据表明，在辅助治疗中，芳香化酶抑制剂（AI）比他莫昔芬更具优势。同样明显的是，与AI相关的肌肉骨骼症状在临床环境中可能是一个重大问题。本文的目的是回顾辅助治疗中关于AI与肌肉骨骼症状的数据。
对有关辅助治疗中AI和肌肉骨骼症状的文献进行综述。
III期试验结果显示，肌肉骨骼症状的发生率低于临床报告。
AI比他莫昔芬具有显著优势。需要更多研究来确定病因，并明确服用AI的女性所报告的肌肉骨骼症状范围。在充分讨论风险和益处后，临床医生和患者应共同做出适当治疗的决定。
